None listed
Conditions
Interventions
Intervention1: Curcumin Capsule: 3.6 gms/day for 8-32 weeks
Control Intervention1: -: -
Control Intervention2: Nil: Nil
Sponsors
DBT
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with histo-pathological confirmed squamous cell carcinoma of head and neck (oral cavity/ pharynx/ larynx) 2. Patients who have advanced incurable cancer of head and neck region at the initial diagnosis or those who have failed all standard cancer specific treatment including chemotherapy, radiotherapy 3. Patient has signed and dated the informed consent document 4. Patient is willing and able to fully participate for the duration of the study 5. Patient with anticipated life of more than two months on clinical assessment by team members
Exclusion criteria
Exclusion criteria: 1. Patient is less than 18 years of age 2. Patient is participating in any other study 3. Patient with non-squamous cell cancers 4. Patient who does not comply with assigned treatment protocol 5. Patient with potential behavior and cognitive impairment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To establish the chemotherapeutic role of Curcumin in advanced head and neck cancers 2. To establish supportive role (enhancement of quality of life) in advanced head and neck cancer 3. To establish the modulation of proven biomarkers in advanced head and neck cancers with Curcumin Timepoint: Baseline, 1st, 2nd, 4th, 6th & 8th week of treatment. Subsequently Quality of life assessment every two months until six month of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| NilTimepoint: Nil | — |
Countries
India
Contacts
Public ContactDr. Sunil K Saini
Principal Investigator
Outcome results
None listed